Big strides in cancer detection and treatment from the tiniest technologies

May 16, 2026 - 04:46

Ten years ago, the idea of using microscopic particles to hunt down cancer cells was still largely a laboratory dream. This week, the MIT Marble Center for Cancer Nanomedicine marked its tenth anniversary by showcasing just how far that dream has come. The celebration featured keynote talks from pioneering researchers Sangeeta Bhatia and Robert Langer, followed by a panel discussion with founders of companies that have spun out from the center's work.

The core promise of nanomedicine is precision. Instead of flooding the body with harsh chemicals, these technologies use particles measured in billionths of a meter to deliver drugs directly to tumors, or to act as tiny sensors that can spot the earliest signs of disease. Bhatia, a leader in the field, highlighted how these tools are moving beyond the lab bench. Her work has led to synthetic biomarkers that can be inhaled or injected, then detected in a simple urine test, offering a non-invasive way to screen for lung cancer and other conditions.

Langer, whose foundational research in drug delivery systems helped launch the field, spoke about the long road from a scientific paper to a product that helps patients. The panel of spinout founders echoed that theme, discussing the challenges of scaling up nanoparticle manufacturing and navigating clinical trials. They pointed to recent successes, including FDA-approved nanoparticle therapies that have improved survival rates for certain ovarian and pancreatic cancers.

The message from the anniversary event was clear: after a decade of steady progress, these tiny technologies are starting to make a big difference in how doctors find and fight cancer, with many more breakthroughs expected in the years ahead.